Tectonic Therapeutic Inc/$TECX

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX

About Tectonic Therapeutic Inc

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Ticker

$TECX
Sector
Health Care
Primary listing
NASDAQ

Industry

Biotechnology
Headquarters
Watertown, United States

Employees

51

ISIN

US8789721086
Website
tectonictx.com

TECX Metrics

BasicAdvanced
$398M
-
-$4.72
-
-

Bulls say / Bears say

Tectonic Therapeutic's lead program, TX45, demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF), supporting its progression into Phase 2 trials. (StreetInsider)
The company maintains a strong cash position, with $306.2 million in cash and cash equivalents as of March 31, 2025, providing a financial runway into the fourth quarter of 2028, including through key Phase 1b and Phase 2 readouts for TX45. (Tectonic Therapeutic Q1 2025 Financial Results)
Tectonic Therapeutic has selected TX2100 as the development candidate for its second program targeting Hereditary Hemorrhagic Telangiectasia (HHT), a genetic bleeding disorder with no approved therapies, indicating a robust pipeline addressing unmet medical needs. (Nasdaq)
The company reported a net loss of $15.9 million for the first quarter of 2025, reflecting the high costs associated with ongoing research and development activities. (Tectonic Therapeutic Q1 2025 Financial Results)
Tectonic Therapeutic's reliance on third-party contract research organizations and manufacturing organizations introduces supply chain dependencies and potential risks that could impact development timelines. (SEC Filing)
The company's focus on early-stage clinical programs means that profitability is years away and heavily dependent on the success of clinical trials and regulatory approvals, which are inherently uncertain. (Panabee)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.

TECX News

AllArticlesVideos
Tectonic Therapeutic Joins Russell 3000® Index

Tectonic Therapeutic Joins Russell 3000® Index

GlobeNewsWire·5 days ago
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025

Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025

GlobeNewsWire·2 months ago
Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights

Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights

GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TECX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs